Is norethindrone acetate a form of birth control for a reproductive‑age woman being treated for endometriosis?

Norethindrone Acetate for Endometriosis: Not Primarily a Contraceptive

Norethindrone acetate is FDA-approved for treating endometriosis symptoms, not as a contraceptive, though it may suppress ovulation at therapeutic doses. 1

Primary Indication and Mechanism

Norethindrone acetate is specifically indicated for treating endometriosis, secondary amenorrhea, and abnormal uterine bleeding—not for contraception 1. The FDA label explicitly states it is "not intended, recommended or approved to be used with concomitant estrogen therapy in postmenopausal women for endometrial protection" 1, distinguishing it from hormone replacement therapy formulations.

Contraceptive Effect: Secondary, Not Primary

While norethindrone acetate may suppress ovulation at the doses used for endometriosis treatment (2.5-5 mg daily) 2, this is a secondary pharmacologic effect, not its intended purpose. The drug label actually contraindicates use during pregnancy and warns patients to "avoid using norethindrone acetate tablets during pregnancy" 1. This creates an important clinical nuance:

• The medication may prevent ovulation at therapeutic doses
• However, it is not FDA-approved or tested as a contraceptive
• Patients should not rely on it for birth control

Critical Clinical Distinction

The 2021 guidelines on premature ovarian insufficiency note that when prescribing hormone replacement therapy with progestins, "women with POI may spontaneously, though infrequently, ovulate" and recommend that "in the absence of a withdrawal bleeding, the patient should be advised to promptly test for pregnancy" 3. This underscores that progestin therapy—even when it suppresses ovulation—should not be considered reliable contraception.

Practical Recommendation for Your Patient

For a reproductive-age woman being treated for endometriosis with norethindrone acetate:

1. Counsel that this is NOT birth control despite potential ovulation suppression
2. Add barrier contraception or an IUD if pregnancy prevention is desired 4
3. Consider switching to combined oral contraceptives if both endometriosis treatment AND contraception are goals—these are proven effective for both purposes 5

The 2000 ACOG guidelines confirm that "oral contraceptives and oral or depot medroxyprogesterone acetate are effective in comparison with placebo" for endometriosis pain relief 5, meaning combined oral contraceptives can serve dual purposes when appropriate.

Evidence for Efficacy in Endometriosis

Multiple studies demonstrate norethindrone acetate's effectiveness for endometriosis symptoms:

• 84-94% pain relief rates 6
• Comparable efficacy to dienogest and extended-cycle oral contraceptives 7, 8, 9
• Significant reduction in endometrioma size 9
• Cost-effective first-line option 8, 10

Bottom line: Treat norethindrone acetate as endometriosis therapy, not contraception. If your patient needs birth control, add a separate contraceptive method or switch to combined oral contraceptives that serve both purposes.